Address Hotels and Resorts Announces the Opening of Address Jabal Omar Makkah Unveiling a Spiritual Haven in the Heart of Makkah
12.7.2023 09:00:00 EEST | Business Wire | Press release
Address Hotels and Resorts is thrilled to announce the opening of its latest architectural and hospitality masterpiece, Address Jabal Omar Makkah, in the holy city of Makkah, Saudi Arabia. Nestled in the iconic Jabal Omar development, this landmark property offers a truly unforgettable experience for pilgrims and travellers alike.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230711493267/en/
Panoramic Kaaba view from Address Jabal Omar Makkah (Photo: AETOSWire)
The largest hotel within the Address Hotels and Resorts portfolio, Address Jabal Omar Makkah boasts an impressive 1,484 rooms and suites. With its striking architectural design, a seamless fusion of ancient Arabian charm and contemporary opulence, the hotel is the tallest building in Jabal Omar and is a breathtaking sight.
One standout feature of Address Jabal Omar Makkah is its proximity to the sacred Holy Kaaba and Al Masjid Al Haram, along with the Makkah Museum, Masjid Al Jinn, Jannat al-Mu'alla Cemetery, and the iconic Abraj Al Bait Towers. Designed by the world-renowned architects Foster & Partners, the towers of Address Jabal Omar Makkah span over 5,000 sqm and the development includes a commercial area featuring a diverse range of shops, showcasing local, regional, and international brands.
Address Jabal Omar Makkah offers a range of exquisitely designed accommodations to suit every traveller’s needs. From luxurious Deluxe Rooms, which provide splendid views of the Holy Kaaba or the Holy City, to indulgent Suites and the magnificent three-bedroom Presidential Suite and four-bedroom Penthouse, guests can immerse themselves in comfort and elegance.
With four restaurants, two lobby lounges, and two club lounges, guests can also savour a wide range of delectable cuisines. The hotel's signature dining venue offers traditional Hejazi cuisine and other Saudi Arabian specialties, where live cooking stations showcase international flavours alongside time-honoured delicacies.
The spa and wellness offerings, including the first-ever Foot Spa by Address Hotels and Resorts, at the hotel are designed to provide guests with a truly holistic experience. With a complimentary Fitness Centre, equipped with the latest Technogym equipment on hand as well, guests can maintain their well-being during their stay.
Address Jabal Omar Makkah is also a premier destination for conferences and events. Whatever the occasion, the hotel’s unparalleled settings and services help create cherished moments. The property's multifunctional meeting spaces are designed to cater to events of any scale. The hotel's creative chefs curate menus tailored to individual preferences, ensuring a flawless and memorable event.
Mark Kirby, Head of Emaar Hospitality, said, “We are delighted to announce the opening of Address Jabal Omar Makkah. Its prime location makes it the preferred choice for those seeking to deepen their spiritual connection. With spacious rooms and suites, multiple dining options, and state-of-the-art prayer facilities, the hotel offers all the amenities necessary for a meaningful and unforgettable pilgrimage experience. Whether guests are here for Hajj, Umrah, or to enhance their spiritual connection, Address Jabal Omar Makkah Hotel is the optimal starting point for their journey.”
The hotel is proud to be a part of Saudi Arabia's Vision 2030, which aims to transform the country's tourism landscape.
To reserve with a 15% discount, click the link, visit our website, or email stayatmakkah@addresshotels.com or call +966-0125531444.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230711493267/en/
Contact information
Mohammad Jamil
Mohammad.j@addresshotels.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
